A randomized clinical trial found that simultaneous administration of mRNA COVID-19 and inactivated influenza vaccines (IIV4) has a similar safety profile to sequential administration.
The NIH has initiated a Phase 1 clinical trial for MPV/S-2P, a novel nasal COVID-19 vaccine, across three U.S. sites, aiming for improved protection against emerging variants.
CanSino Biologics Inc. (CanSinoBIO) has received approval from China's medical products regulator to begin clinical trials for its mRNA COVID-19 vaccine candidate.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.